Fifty 1 Labs $FITY

Bridging science & business. With decades in natural health and supplement R&D, Dr. Gagnier ensures FIFTY1 Labs ($FITY) keeps research rigor at the core of real-world product development. Science you can trust. Results you can see. #FITY #NutritionalScience #WellnessInnovation

AI + clinical science = the future of wellness. Dr. Gagnier’s expertise in musculoskeletal health, surgical safety, and perioperative research positions FIFTY1 Labs ($FITY) to deliver faster, smarter, more accurate results. #FITY #AIinHealth #LongevityScience #HealthTech

Why patient-reported outcomes matter NOW in wellness: Dr. Gagnier explains how valid, reliable measures capture real patient experiences—key to proving intervention efficacy. Weak measures = weak science. We're raising the bar at FIFTY 1 Labs! $FITY #HealthScience

Meet Dr. Joel Gagnier, CSO of FIFTY 1 Labs! From psychometrics & philosophy to naturopathic medicine, PhD in clinical epidemiology, and tenure at U Michigan & Western U. His journey built expertise in musculoskeletal health & research methods. Building the future of wellness! $FITY #FIFTY1Labs

$FITY CEO Paul Arora sits down with Dr. Joel Gagnier, our new Chief Science Officer, as he shares how decades of evidence-based research, industry leadership, and regulatory experience have prepared him to lead scientific innovation at Fifty1 AI Labs. #FITY #AIHealth #Biotech #Innovation #HealthScience #OTCMarkets

$FITY is excited to welcome Dr. Joel Gagnier, ND, MSc, PhD, as Chief Science Officer at Fifty1 AI Labs. With over CAD $20M in research grants, 210+ peer-reviewed publications, and deep expertise in AI-driven clinical trials, Dr. Gagnier will help shape the future of personalized wellness and pain management. globenewswire.com/news-release/2… #AIHealth #PrecisionMedicine #HealthInnovation

Massive step forward for $FITY! Fifty 1 Labs, Inc. engages PCAOB auditing firm for 2024-2025 audits, gearing up for uplist to OTCQB. Unlocking visibility, liquidity, & investor trust in our AI-driven biotech mission! "Committed to transparency & transforming health." – CEO Paul Arora globenewswire.com/news-release/2… #FITY #Biotech #AI #OTCQB

$FITY is leading the charge in AI-driven oncology! Leadership's new primer simplifies transportability principles to bridge data gaps worldwide, accelerating access to life-saving treatments in rare diseases & underserved areas. globenewswire.com/news-release/2… #HealthTech #Innovation #RealWorldEvidence

Fifty1 Labs ($FITY) partners with LUNR Aerospace to revolutionize space medicine with AI-driven drug repurposing! Targeting a $2B market by 2032, this collaboration leverages orbital research to advance astronaut health and dual-use innovations. Read more: globenewswire.com/news-release/2… #FITY #SpaceTech #Biotech

$FITY CEO Paul Arora breaks down the strategy: OTCQB by Q1 2026 → NASDAQ next. Why uplisting matters? Let’s talk momentum. ⬇️ #FITY #Uplisting #Growth

The goal is clear: position $FITY for transformative growth while creating long-term shareholder value. Big vision. Real momentum. #FITY #ShareholderValue #Uplisting

📊 Uplisting unlocks: • Higher liquidity for investors • Greater access to capital • Stronger credibility with institutions & partners These are the levers fueling our R&D + acquisitions pipeline. #FITY #Innovation

Ed Mills, Scientific Advisor at $FITY, calls our team “a spectacular group of high-level scientists” whose decades of experience bridge AI, global health, and clinical medicine. United by one language, we’re driving innovation that matters. youtu.be/eFI4qo1RSD0 #FITY #AI #GlobalHealth #FunctionalMedicine

$FITY & the Gates Foundation complete the largest-ever Sickle Cell study, mapping 10+ years of patient data to unlock faster, affordable treatments. AI + world-class partnerships = hope for millions worldwide. globenewswire.com/news-release/2… #GlobalHealth #AIDrugDiscovery #SickleCell #PrecisionMedicine

At Fifty1Labs (OTC: $FITY), our academic partnerships drive groundbreaking innovation. Senior Scientist James Orbinski explains how our team’s rigorous pursuit of truth—through data, hypothesis, and coherent science—unlocks the potential of AI to repurpose compounds and deliver equitable, impactful solutions. #AIHealth #ScienceForGood #FITY

$FITY CEO breaks down what sets Fifty1 AI Labs apart: ✔ Off-patent drug repurposing — faster, safer, cheaper ✔ Real-world data + adaptive trials = regulatory acceleration ✔ Full-stack: from discovery to delivery to patient outcomes ✔ Global health roots to reach underserved markets This is just the beginning. #FITY #DrugRepurposing #AIHealth #OTCMarkets #Innovation

Huge milestone for $FITY! Fifty1 Labs & BioSpark AI unlock 2,000+ real-world treatment pathways, transforming 10,000+ case reports into a queryable database. This AI-driven breakthrough accelerates drug repurposing & functional medicine innovation. #AI #HealthTech #FITY Read more: globenewswire.com/news-release/2…